Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 10:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–34 of 10 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: KRAS G12D Clear all

Recruiting Phase 1 Interventional

A Study of ASP3082 in Adults With Advanced Solid Tumors

NCT05382559

View directory record Official record

Conditions: Solid Tumor
Interventions: Setidegrasib, Cetuximab, Leucovorin, Oxaliplatin, Fluorouracil, Irinotecan, Nanoparticle albumin-bound-paclitaxel, Gemcitabine, Docetaxel, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Liposomal Irinotecan; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older

Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 23
States / cities: Duarte, California • Santa Monica, California • Denver, Colorado + 17 more

Source: ClinicalTrials.gov public record

Updated Apr 13, 2026 · Synced May 21, 2026, 10:12 PM EDT

Active, not recruiting Phase 1Phase 2 Interventional

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864

View directory record Official record

Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
Interventions: ELI-002 7P; Drug
Lead sponsor: Elicio Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 28
States / cities: Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more

Source: ClinicalTrials.gov public record

Updated May 18, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

QTX3034 in Patients With KRAS G12D Mutation

NCT06227377

View directory record Official record

Conditions: Solid Tumors
Interventions: QTX3034, Cetuximab; Drug · Combination Product
Lead sponsor: Quanta Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 11 more

Source: ClinicalTrials.gov public record

Updated Apr 26, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

NCT06447662

View directory record Official record

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more

Source: ClinicalTrials.gov public record

Updated Apr 19, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 3 Interventional

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073

View directory record Official record

Conditions: Solid Tumors
Interventions: INCB161734, Placebo, Investigator's choice of chemotherapy; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older

Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 65
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 51 more

Source: ClinicalTrials.gov public record

Updated May 7, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

NCT06619587

View directory record Official record

Conditions: Solid Tumor
Interventions: Phase I Arm A, Phase I Arm B; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: La Jolla, California • Denver, Colorado • New Haven, Connecticut + 9 more

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 21, 2026, 10:12 PM EDT

Terminated Phase 1 Interventional

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

NCT05737706

View directory record Official record

Conditions: Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer, Pancreatic Adenocarcinoma
Interventions: MRTX1133; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • New Haven, Connecticut • Lady Lake, Florida + 9 more

Source: ClinicalTrials.gov public record

Updated Apr 5, 2025 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1 Interventional

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

NCT07094204

View directory record Official record

Conditions: Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions: ASP5834, panitumumab; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older

Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more

Source: ClinicalTrials.gov public record

Updated May 17, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

NCT06973564

View directory record Official record

Conditions: Advanced Solid Tumors
Interventions: JAB-23E73; Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older

Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more

Source: ClinicalTrials.gov public record

Updated Jan 15, 2026 · Synced May 21, 2026, 10:12 PM EDT

Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

NCT07020221

View directory record Official record

Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine, Gemcitabine + Nab-paclitaxel; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more

Source: ClinicalTrials.gov public record

Updated Apr 21, 2026 · Synced May 21, 2026, 10:12 PM EDT